Journal article
Early and sustained Lactobacillus plantarum probiotic therapy in critical illness: the randomised, placebo-controlled, restoration of gut microflora in critical illness trial (ROCIT)
Intensive Care Medicine, Vol.47, pp.307-315
2021
Abstract
Purpose
In adults requiring treatment in an intensive care unit, probiotic therapy using Lactobacillus plantarum 299v may reduce nosocomial infection. The aim of this study was to determine whether early and sustained L. plantarum 299v therapy administered to adult ICU patients increased days alive and at home.
Methods
A multicentre, parallel group, placebo-controlled, randomised clinical trial was conducted. Adult patients within 48 h of intensive care admission and expected to require intensive care beyond the day after recruitment were eligible to participate. L plantarum 299v or placebo were administered immediately after enrolment and continued for 60 days. The primary outcome was days alive and out of hospital to Day 60 (DAOH60). Secondary outcomes included nosocomial infections.
Results
The median [interquartile range (IQR)] number of DAOH60 in the probiotic (n = 110) and placebo group (n = 108) was 49.5 (IQR 37.0–53.0) and 49.0 (IQR 43.8–53.0) respectively, between-group difference of 0.0 [95% confidence interval (CI) − 6.10 to 7.1, P = 0.55]. Nosocomial infection occurred in 8 (7.3%) and 5 (4.6%) of the probiotic and placebo group participants, respectively, odds ratio 1.62 (95% CI 0.51–5.10), P = 0.57. There were no serious, or probiotic-associated adverse events.
Conclusion
Early and sustained untargeted administration of probiotic therapy with Lactobacillus plantarum 299v to adult patients admitted to the ICU is safe, but not associated with improved patient outcomes.
Details
- Title
- Early and sustained Lactobacillus plantarum probiotic therapy in critical illness: the randomised, placebo-controlled, restoration of gut microflora in critical illness trial (ROCIT)
- Authors/Creators
- E. Litton (Author/Creator)M. Anstey (Author/Creator)D. Broadhurst (Author/Creator)A. Chapman (Author/Creator)A. Currie (Author/Creator)J. Ferrier (Author/Creator)J. Gummer (Author/Creator)A. Higgins (Author/Creator)J. Lim (Author/Creator)L. Manning (Author/Creator)E. Myers (Author/Creator)K. Orr (Author/Creator)A-M Palermo (Author/Creator)A. Paparini (Author/Creator)S. Pellicano (Author/Creator)E. Raby (Author/Creator)A. Rammohan (Author/Creator)A. Regli (Author/Creator)B. Richter (Author/Creator)S. Salman (Author/Creator)T. Strunk (Author/Creator)S. Waterson (Author/Creator)D. Weight (Author/Creator)B. Wibrow (Author/Creator)F. Wood (Author/Creator)
- Publication Details
- Intensive Care Medicine, Vol.47, pp.307-315
- Publisher
- Springer
- Identifiers
- 991005543144907891
- Copyright
- © 2021 Springer-Verlag GmbH Germany, part of Springer Nature
- Murdoch Affiliation
- School of Medical, Molecular and Forensic Sciences; Health Futures Institute
- Language
- English
- Resource Type
- Journal article
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites
Metrics
109 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- International collaboration
- Citation topics
- 1 Clinical & Life Sciences
- 1.120 Inflammatory Bowel Diseases & Infections
- 1.120.267 Lactic Acid Bacteria
- Web Of Science research areas
- Critical Care Medicine
- ESI research areas
- Clinical Medicine